A new treatment for low parathyroid hormone levels in patients with hypoparathyroidism
Official title: Long-acting PTH for hypoparathyroidism
Funded at Extend Biosciences, INC. · NIH-10822753 · Data updated 2026-11-12
This study is testing a new way to deliver parathyroid hormone continuously for people with hypoparathyroidism, aiming to help balance calcium and phosphorus levels in the body and make life easier compared to taking multiple daily supplements.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Extend Biosciences, INC. NIH-funded |
| Lab location | 1 site (Newton, UNITED STATES) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $999,615 |
| NIH project number | 1R44DK138647-01 |
| Project ID | NIH-10822753 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hypoparathyroidism who struggle with managing their condition through current supplementation methods.
✕Less likely to help
Patients who do not have hypoparathyroidism or those whose condition is adequately managed with existing treatments may not benefit from this research.
What this research studies
This research investigates a long-acting formulation of parathyroid hormone (PTH) for patients suffering from hypoparathyroidism, a condition characterized by insufficient PTH production. The approach involves continuous infusion of PTH to mimic natural hormone levels, potentially restoring normal calcium and phosphorus levels in the body. Current treatments often require multiple daily supplements of calcium and vitamin D, which do not address the root cause of the hormone deficiency. By using a pump to deliver PTH continuously, the study aims to improve patient outcomes and reduce the complications associated with traditional therapies.
Why it matters
Potential benefit: If successful, this research could significantly improve the management of hypoparathyroidism, reducing the need for multiple supplements and minimizing related health complications.
How similar studies have gone: Previous clinical trials have shown promising results with continuous infusion of PTH, indicating that this approach may be effective in managing hypoparathyroidism.
Where this research is happening
-
Extend Biosciences, INC.
Newton, United States Active
Researchers
- Principal investigator: Hales, Laura M — Extend Biosciences, INC.
- Study coordinator: Hales, Laura M
Related research
Other NIH-funded projects on the same topics.
-
Parathyroid cell transplantation to treat hypoparathyroidism
A doctor-scientist team at a major university plans a parathyroid cell transplant to help people with chronic hypoparathyroidism reduce dependence on calcium and vitamin D supplements.
-
Long-acting parathyroid hormone treatment for hypoparathyroidism
A long-lasting parathyroid hormone medicine designed to help people with hypoparathyroidism keep their calcium levels steady and take fewer pills.
-
Understanding hypoparathyroidism effects on calcium and organ health
This project follows people with hypoparathyroidism to learn how low parathyroid hormone and calcium levels affect organs and overall health over time.
-
Understanding the effects of hypoparathyroidism on health outcomes.
This study is looking at hypoparathyroidism, a rare condition that causes low hormone and calcium levels, to better understand how it affects health and leads to problems like kidney issues and heart complications, so we can improve how it's diagnosed and treated for those living with it.
-
German Hypoparathyroidism Registry
This registry in Germany collects information from adults with chronic hypoparathyroidism or pseudohypoparathyroidism to better understand how the condition affects people over time and to support future research.
-
Encaleret for Chronic Hypoparathyroidism: Testing if it helps symptoms and safety
This study tests whether taking encaleret pills can help people with chronic hypoparathyroidism, while being safe and tolerable.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.